{"filing":{"accession_number":"0001062993-26-002900","cik":"0001997296","ticker":"MDCXW","company_name":"Medicus Pharma Ltd.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1997296/000106299326002900/form8k.htm"},"events":[{"id":8652,"run_id":7599,"accession_number":"0001062993-26-002900","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Medicus Pharma received written notice from Nasdaq on May 20, 2026, that it failed to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35,000,000 for 30 consecutive business days and does not satisfy alternative listing standards. The company has 180 days until November 16, 2026, to regain compliance or face delisting.","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-05-27","submitted_at":null,"items":[{"id":1784,"accession_number":"0001062993-26-002900","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Medicus Pharma received written notice from Nasdaq on May 20, 2026, that it failed to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35,000,000 for 30 consecutive business days and does not satisfy alternative listing standards. The company has 180 days until November 16, 2026, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, with material consequences for continued trading and investor access.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:04.824453+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":8653,"run_id":7599,"accession_number":"0001062993-26-002900","anchor_item_number":"1.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"summary":"Medicus Pharma entered into a material definitive agreement creating a $22.864 million secured debt financing with embedded equity conversion features, including Note Exchange rights allowing conversion of the B Note into A Notes at a 2-to-1 formula and redemption rights tied to stock price and trading volume. The combination of debt and dilutive equity mechanics creates financial and capital structure implications.","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-05-27","submitted_at":null,"items":[{"id":1782,"accession_number":"0001062993-26-002900","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 1.01 typically signals M\u0026A activity or material acquisition/disposition, but the filing provides no substantive details—only a cross-reference to Item 2.03 (Creation of a Direct Financial Obligation). Without the actual agreement text or Item 2.03 content, the specific nature of the material definitive agreement cannot be determined. The event is marked material because Item 1.01 filings are inherently material, but the event_type cannot be confidently assigned to ma_activity or covenant_breach without additional disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:04.824453+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1783,"accession_number":"0001062993-26-002900","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The filing discloses a $22.864 million secured debt financing with embedded equity conversion features (Note Exchange rights allowing conversion of the B Note into A Notes at a 2-to-1 formula, plus Monthly and Limited Redemption rights tied to stock price and trading volume). While the primary obligation is debt, the conversion mechanics and redemption features tied to equity performance create dilutive pressure. However, this is fundamentally a debt issuance under Item 2.03, not an equity issuance under Item 3.02, creating genuine uncertainty about whether \"dilutive_issuance\" or \"other_material\" is more appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:04.824453+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1782,"accession_number":"0001062993-26-002900","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 1.01 typically signals M\u0026A activity or material acquisition/disposition, but the filing provides no substantive details—only a cross-reference to Item 2.03 (Creation of a Direct Financial Obligation). Without the actual agreement text or Item 2.03 content, the specific nature of the material definitive agreement cannot be determined. The event is marked material because Item 1.01 filings are inherently material, but the event_type cannot be confidently assigned to ma_activity or covenant_breach without additional disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:04.824453+00:00","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-05-27"},{"id":1783,"accession_number":"0001062993-26-002900","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The filing discloses a $22.864 million secured debt financing with embedded equity conversion features (Note Exchange rights allowing conversion of the B Note into A Notes at a 2-to-1 formula, plus Monthly and Limited Redemption rights tied to stock price and trading volume). While the primary obligation is debt, the conversion mechanics and redemption features tied to equity performance create dilutive pressure. However, this is fundamentally a debt issuance under Item 2.03, not an equity issuance under Item 3.02, creating genuine uncertainty about whether \"dilutive_issuance\" or \"other_material\" is more appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:04.824453+00:00","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-05-27"},{"id":1784,"accession_number":"0001062993-26-002900","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Medicus Pharma received written notice from Nasdaq on May 20, 2026, that it failed to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35,000,000 for 30 consecutive business days and does not satisfy alternative listing standards. The company has 180 days until November 16, 2026, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, with material consequences for continued trading and investor access.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:08:04.824453+00:00","company_name":"Medicus Pharma Ltd.","ticker":"MDCXW","filing_date":"2026-05-27"}]}